leadf
logo-loader
AIM:ORPH FRA:CRO

Open Orphan PLC

Receive alerts
Market:
AIM
Market Cap:
£140.31 m
Price
20.92 GBX
Change
-3.84%
52 weeks high
48.00
52 weeks low
15.00

In brief

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.

Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. 

Snapshot

  • Open Orphan wins £5.7mln flu trial contract, revenues soar
  • Open Orphan moves forward with government-backed COVID-19 vaccine human challenge study
  • Open Orphan reveal 'very good first half, firmly profitable, cash in bank and record revenues!'